Abstract:The majority of human breast cancers are dependent on hormone stimulated estrogen receptor alpha (ER) and are sensitive to its inhibition. Treatment resistance arises in most advanced cancers due to genetic alterations that promote ligand independent activation of ER itself or ER target genes. Whereas re-targeting of the ER ligand binding domain (LBD) with newer ER antagonists can work in some cases, these drugs are largely ineffective in many genetic backgrounds including ER fusions that lose the LBD or in cancers that hyperactivate ER targets. By identifying the mechanism of ER translation, we herein present an alternative strategy to target ER and difficult to treat ER variants. We find that ER translation is cap independent and mTOR inhibitor insensitive, but dependent on 5'UTR elements and sensitive to pharmacologic inhibition of the translation initiation factor eIF4A, an mRNA helicase. EIF4A inhibition rapidly reduces expression of ER and short lived targets of ER such as cyclin D1 and other components of the cyclin D CDK complex in breast cancer cells. These effects translate into suppression of growth of a variety of ligand independent breast cancer models including those driven by ER fusion proteins that lack the ligand binding site. The efficacy of eIF4A inhibition is enhanced when it is combined with fulvestrant, an ER degrader. Concomitant inhibition of ER synthesis and induction of its degradation causes synergistic and durable inhibition of ER expression and tumor growth. The clinical importance of these findings is confirmed by results of an early clinical trial ( ) of the selective eIF4A inhibitor zotatifin in patients with estrogen receptor positive metastatic breast cancer. Multiple clinical responses have been observed on combination therapy including durable regressions. These data suggest that eIF4A inhibition could be a useful new strategy for treating advanced ER+ breast cancer.

Targeting Translation: Eif4e As an Emerging Anticancer Drug Target.

Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy

Translational Regulator Eif2α in Tumor

Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers

Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers

The eIF4E2-Directed Hypoxic Cap-Dependent Translation Machinery Reveals Novel Therapeutic Potential for Cancer Treatment

Small-Molecule Inhibitors Targeting Eif4a in Leukemia

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

Eukaryotic translation initiation factors and cancer.

Eukaryotic Translation Initiation Factors and Tumor

Targeting EIF4F complex in non-small cell lung cancer cells.

Eukaryotic Translation Initiation Factor 3 and Tumor

eIF3a: A new anticancer drug target in the eIF family.

Dissecting Eif4e Action In Tumorigenesis

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

Eif4e Knockdown Decreases Breast Cancer Cell Growth Without Activating Akt Signaling.

[Role of Eukaryotic Translation Initiation Factor 4G in Tumor].

Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.

Targeting Translation of mRNA as a Therapeutic Strategy in Cancer

Phospho-eIF4E: a New Target for Acute Myeloid Leukemia.

Eif4e Binding Protein 1 Expression is Associated with Clinical Survival Outcomes in Colorectal Cancer